# reload+after+2024-01-21 04:44:05.103674
address1§8, rue de la Croix Jarry
city§Paris
zip§75013
country§France
phone§33 1 81 69 16 00
fax§33 1 81 69 16 06
website§https://www.cellectis.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
fullTimeEmployees§231
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Andre  Choulika Ph.D.', 'age': 58, 'title': 'Co-Founder, CEO & Director', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 744016, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. David J. D. Sourdive Ph.D.', 'age': 56, 'title': 'Deputy CEO, Executive VP of CMC & Manufacturing and Director', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 528920, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Bing C. Wang M.B.A., Ph.D.', 'age': 46, 'title': 'Chief Financial Officer', 'yearBorn': 1977, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Valerie  Cros', 'title': 'Principal Financial Officer & Principal Accounting Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jean Charles Epinat', 'title': 'Chief Technological Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Philippe  Duchateau Ph.D.', 'age': 60, 'title': 'Chief Scientific Officer', 'yearBorn': 1963, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Stephan  Reynier M.Sc.', 'age': 54, 'title': 'Chief Regulatory & Pharmaceutical Compliance Officer', 'yearBorn': 1969, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Marie-Bleuenn  Terrier', 'age': 41, 'title': 'General Counsel & Secretary of the Board of Directors', 'yearBorn': 1982, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Pascalyne  Wilson', 'title': 'Director of Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Kyung  Nam-Wortman', 'age': 53, 'title': 'Executive VP & Chief Human Resources Officer', 'yearBorn': 1970, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§10
boardRisk§10
compensationRisk§6
shareHolderRightsRisk§9
overallRisk§10
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§3.079
priceToSalesTrailing12Months§8.756428
currency§USD
dateShortInterest§1702598400
forwardEps§-1.12
exchange§NGM
quoteType§EQUITY
shortName§Cellectis S.A.
longName§Cellectis S.A.
firstTradeDateEpochUtc§1427203800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§a7dc8288-eba8-3f16-a312-d116920d6e16
gmtOffSetMilliseconds§-18000000
targetHighPrice§11.0
targetLowPrice§3.0
targetMeanPrice§7.25
targetMedianPrice§6.5
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§8
quickRatio§2.032
grossMargins§0.94858
ebitdaMargins§-2.63747
trailingPegRatio§None
